What is an appropriate outpatient treatment plan for blood‑pressure control and severe aortic stenosis in an 81‑year‑old woman with hypertension, hyperlipidemia, recent cerebrovascular accident, currently taking low‑dose aspirin (acetylsalicylic acid) 81 mg daily, atorvastatin 10 mg daily, and metoprolol tartrate 12.5 mg twice daily, and echocardiographic findings of severe aortic stenosis, moderate‑to‑severe concentric left‑ventricular hypertrophy, preserved ejection fraction (65 %), severe left‑atrial enlargement, mild right‑atrial enlargement, mild tricuspid regurgitation with estimated pulmonary artery pressure of 40 mm Hg, and grade 1 diastolic dysfunction?

Outpatient Management Plan for Severe Aortic Stenosis and Hypertension Post-CVA

This 81-year-old woman requires urgent cardiology referral for aortic valve replacement evaluation while carefully optimizing blood pressure control with her current beta-blocker, targeting systolic BP 130-139 mmHg, and avoiding aggressive BP lowering that could compromise cardiac output in severe AS.

Immediate Priorities

1. Aortic Valve Replacement Evaluation

Refer immediately to cardiology/Heart Team for valve intervention assessment 1. This patient meets Class I indication for intervention: she has severe aortic stenosis and is symptomatic (recent CVA in the setting of severe AS with elevated pulmonary pressures and cardiac remodeling constitutes a cardiovascular event) 1.

Given her age (81 years), the Heart Team should evaluate for:

• TAVR as the preferred approach if she has reasonable transfemoral access, given her age and recent CVA 1
• Surgical risk assessment using STS or EuroSCORE II
• The decision between SAVR and TAVR should favor TAVR in elderly patients suitable for transfemoral access 1

Critical point: Do not delay valve intervention evaluation. The combination of severe AS, severe left atrial enlargement, elevated PA pressures (40 mmHg), and recent CVA indicates advanced disease with extra-valvular cardiac damage.

2. Blood Pressure Management Strategy

Target systolic BP: 130-139 mmHg (avoid lower targets) 2. This patient's current metoprolol dose (12.5 mg BID = 25 mg total daily) is substantially below the therapeutic range for hypertension.

Medication Adjustments:

Uptitrate metoprolol tartrate gradually:

• Current dose: 12.5 mg BID (25 mg/day total)
• Increase to 25 mg BID (50 mg/day total) initially 3
• The usual effective dosage range is 100-450 mg/day for hypertension 3
• Monitor BP weekly and uptitrate by 25-50 mg increments until target BP achieved 3
• Beta-blockers are well-tolerated in severe AS and beneficial post-CVA 2, 4

If additional BP control needed after optimizing metoprolol:

• Add ACE inhibitor or ARB (preferred second agent) 5, 2, 6
• ACE inhibitors/ARBs improve survival both before and after valve intervention in AS patients 2
• They are the most well-studied antihypertensive class in severe AS 6
• Start low dose given age and renal considerations

Avoid:

• Calcium channel blockers (associated with lower survival in AS) 2
• Aggressive diuretic use (may be disadvantageous with LVH and smaller LV cavity) 2
• Systolic BP <130 mmHg (associated with worse outcomes in severe AS) 2, 7

3. Continue Current Medications

Aspirin 81 mg daily: Continue for secondary stroke prevention

Atorvastatin 10 mg daily: This dose is suboptimal post-CVA

• Increase to atorvastatin 40-80 mg daily for high-intensity statin therapy 8
• High-intensity statin therapy is indicated post-CVA for secondary prevention
• The current 10 mg dose provides only moderate-intensity therapy

Monitoring Plan

Weekly for first month:

• Blood pressure monitoring (home BP log preferred)
• Assess for symptoms: dyspnea, chest pain, syncope, presyncope
• Heart rate monitoring (avoid excessive bradycardia <50 bpm)

Monthly until stable:

• BP control assessment
• Symptom evaluation
• Medication tolerance

Red flags requiring urgent evaluation:

• New or worsening dyspnea
• Syncope or presyncope
• Chest pain
• Decompensated heart failure signs
• Systolic BP consistently <130 mmHg or >140 mmHg

Key Clinical Considerations

Why This BP Target?

Observational evidence in severe AS suggests systolic BP 130-139 mmHg and diastolic 70-90 mmHg represent optimal targets 2. Lower BP targets should be avoided because:

• Lower mean arterial pressure predicts higher post-AVR mortality 7
• Patients need adequate systemic vascular resistance to maintain cardiac output against severe outflow obstruction
• This patient's preserved EF (65%) with severe AS indicates she's maintaining stroke volume through adequate afterload

Why Beta-Blockers Are Appropriate Here

Despite historical concerns, beta-blockers are safe and potentially beneficial in severe AS 2, 4:

• Well-tolerated in AS patients
• Particularly appropriate given her recent CVA and likely coronary disease risk
• May help with diastolic dysfunction (grade 1 present)
• The 2025 ACC/AHA guidelines support beta-blocker use in hypertension with preserved EF 5

Why ACE-I/ARB as Second-Line

Renin-angiotensin system inhibitors are the most evidence-based add-on therapy 2, 6, 4:

• Improve survival before and after valve intervention
• May slow AS progression
• Beneficial for LV remodeling
• Safe when initiated carefully with BP monitoring

Common Pitfalls to Avoid

1. Delaying valve intervention referral: This patient needs evaluation now, not after "optimizing medical management"
2. Over-aggressive BP lowering: Targeting <130 mmHg systolic may worsen outcomes 2
3. Using calcium channel blockers: Associated with lower survival in AS 2
4. Undertreating with current subtherapeutic doses: Both metoprolol and atorvastatin are dosed too low
5. Assuming AS is asymptomatic: CVA in severe AS with cardiac remodeling represents symptomatic disease

The combination of severe AS, severe atrial enlargement, elevated PA pressures, and recent CVA indicates this patient is at high risk and requires both urgent valve intervention evaluation and careful BP optimization—not aggressive lowering.